ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicImproving Efficacy and Expanding the Reach of T-Cell Therapeutics for Solid Tumors: An End-to-End PerspectiveView all articles
Comprehensive Self-Antigen Screening to Assess Cross-Reactivity in Promiscuous T-cell Receptors
Provisionally accepted- 1Canada's Michael Smith Genome Sciences Centre, Vancouver, Canada
- 2Simon Fraser University Department of Molecular Biology and Biochemistry, Burnaby, Canada
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
T cell receptor (TCR) therapeutics are an emerging modality of biologic and cell-based medicines with the unique ability to target intracellular antigens and finely discriminate between healthy and infected or mutated cells. An obstacle to the development of new TCR therapeutics is the difficulty in engineering these proteins for enhanced therapeutic efficacy while avoiding introduction of unexpected off-target autoreactivity. In this study, we conduct functional high-throughput screening to profile all possible genome-encoded peptides for ability to trigger response in an engineered candidate therapeutic TCR and assess risk of off-target toxicity. We used multiple approaches for constructing comprehensive self-antigen cell libraries and highlight key considerations for designing toxicity screening campaigns using high-throughput TCR profiling in a live cell context. We then use Tope-seq to screen epitope libraries against a model therapeutic candidate TCR and show that this strategy can be used to detect known cross-reactive epitopes from libraries of >5 x 105 unique peptide-coding sequences at a significance threshold of p < 0.01 in first-pass bulk screening. We also incorporate strategies for iterative biopanning and bioinformatic refinement to improve sensitivity and accuracy and demonstrate here the first proof-of-principle for functional TCR screening on a library of >2 x 107 peptide-coding DNA fragments, further advancing the potential of in vitro approaches to perform unbiased TCR epitope discovery.
Keywords: Adaptive ImmuneRepertoires, cell therapy, epitope discovery, Preclinical development, T cell receptor
Received: 07 Oct 2025; Accepted: 05 Dec 2025.
Copyright: © 2025 Sharma, Teng, Round, Sneddon, Brown, Sivasothy and Holt. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Govinda Sharma
Robert Holt
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
